Oke O, Sekh M, Johnson B, Adeyemo S
Cureus. 2024; 16(2):e55256.
PMID: 38558723
PMC: 10981500.
DOI: 10.7759/cureus.55256.
Levin C, Wai J, Jones J, Comer S
Drug Alcohol Depend. 2019; 204:107538.
PMID: 31513980
PMC: 7017784.
DOI: 10.1016/j.drugalcdep.2019.06.040.
Schatzberg A, Charles D
Psychopharmacol Bull. 2018; 48(1):64-153.
PMID: 29382960
PMC: 5765435.
Albertson T, Chenoweth J, Ford J, Owen K, Sutter M
J Med Toxicol. 2014; 10(4):369-81.
PMID: 25238670
PMC: 4252292.
DOI: 10.1007/s13181-014-0430-3.
Mannelli P, Peindl K, Wu L, Patkar A, Gorelick D
Am J Drug Alcohol Abuse. 2012; 38(3):200-5.
PMID: 22233189
PMC: 3578306.
DOI: 10.3109/00952990.2011.644003.
Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha R, Kimmerling A, Doebrick C, Kosten T
Psychopharmacology (Berl). 2006; 190(4):569-74.
PMID: 17136399
DOI: 10.1007/s00213-006-0640-8.
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
Amass L, Ling W, Freese T, Reiber C, Annon J, Cohen A
Am J Addict. 2004; 13 Suppl 1:S42-66.
PMID: 15204675
PMC: 1255908.
DOI: 10.1080/10550490490440807.
Treatment of heroin (diamorphine) addiction: current approaches and future prospects.
Gonzalez G, Oliveto A, Kosten T
Drugs. 2002; 62(9):1331-43.
PMID: 12076182
DOI: 10.2165/00003495-200262090-00004.
The medical management of adolescent heroin dependence.
Rowan A, Fudala P, Mulligan J
Curr Psychiatry Rep. 2000; 2(6):527-30.
PMID: 11123006
DOI: 10.1007/s11920-000-0013-7.
Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine- and morphine-dependent rats.
Harris G, Aston-Jones G
Psychopharmacology (Berl). 1993; 113(1):131-6.
PMID: 7862819
DOI: 10.1007/BF02244345.
Primary care-based ambulatory opioid detoxification: the results of a clinical trial.
OConnor P, Waugh M, Carroll K, Rounsaville B, Diagkogiannis I, Schottenfeld R
J Gen Intern Med. 1995; 10(5):255-60.
PMID: 7616334
DOI: 10.1007/BF02599882.
The role of naltrexone in the management of drug abuse.
Ginzburg H, MACDONALD M
Med Toxicol. 1987; 2(2):83-92.
PMID: 3553834
DOI: 10.1007/BF03260007.
Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal.
Taylor J, Elsworth J, Garcia E, Grant S, Roth R, Redmond Jr D
Psychopharmacology (Berl). 1988; 96(1):121-34.
PMID: 3147472
DOI: 10.1007/BF02431544.
Opiate withdrawal: inpatient versus outpatient programmes.
Brewer C
Br Med J (Clin Res Ed). 1986; 293(6543):391.
PMID: 3089534
PMC: 1341074.
DOI: 10.1136/bmj.293.6543.391-a.
Effects of clonidine and morphine on opioid withdrawal in rhesus monkeys.
Katz J
Psychopharmacology (Berl). 1986; 88(3):392-7.
PMID: 3083461
DOI: 10.1007/BF00180844.
Neuroleptic-induced akathisia: a review.
Adler L, Angrist B, Reiter S, Rotrosen J
Psychopharmacology (Berl). 1989; 97(1):1-11.
PMID: 2565586
DOI: 10.1007/BF00443404.
The effect of ketotifen in rodent models of anxiety and on the behavioural consequences of withdrawing from treatment with drugs of abuse.
Costall B, Kelly M, Onaivi E, Naylor R
Naunyn Schmiedebergs Arch Pharmacol. 1990; 341(6):547-51.
PMID: 2392157
DOI: 10.1007/BF00171735.
Yohimbine co-treatment during chronic morphine administration attenuates naloxone-precipitated withdrawal without diminishing tail-flick analgesia in rats.
Taylor J, Lewis V, Elsworth J, Pivirotto P, Roth R, Redmond Jr D
Psychopharmacology (Berl). 1991; 103(3):407-14.
PMID: 2057541
DOI: 10.1007/BF02244297.
Ambulatory opiate detoxification and primary care: a role for the primary care physician.
OConnor P, Waugh M, Schottenfeld R, Diakogiannis I, Rounsaville B
J Gen Intern Med. 1992; 7(5):532-4.
PMID: 1403211
DOI: 10.1007/BF02599459.
Chronic infusion of clonidine does not alleviate spontaneous morphine withdrawal symptoms in rats.
van der Laan J, Jansen vant Land C
Psychopharmacology (Berl). 1992; 108(3):283-8.
PMID: 1355921
DOI: 10.1007/BF02245113.